FDA’s Next Accelerated Approval Process: “Targeted Cancer Drugs”?
Executive Summary
SAN ANTONIO - Former FDA Commissioners David Kessler and Mark McClellan are urging the agency to develop a new process for accelerated cancer drug approval to take advantage of biomarker identification of specific patient populations and drug activity